HEALTH PROFESSIONAL · SOURCE READING

BRAF inhibitors

Source: Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 2, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Unresectable Stage III, Stage IV, and Recurrent Melanoma / Treatment Options for Unresectable Stage III, Stage IV, and Recurrent Melanoma / Signal transduction inhibitors

Treatment with BRAF inhibitors is discouraged for patients with wild-type BRAF melanoma because data from preclinical models have demonstrated that BRAF inhibitors can enhance rather than downregulate the MAPK pathway in tumor cells with wild-type BRAF and upstream RAS pathogenic variants.[17-20]

Source links and citations

Continue within this section

Vemurafenib →Dabrafenib →

Publication references

Read the original reference and check its publication notices.

Preserved source evidence · Not medical advice